

ROOM GIOTTO - AKI PATH

SESSION 1 - AKI in SEPSIS

Chairmen: *J.L. Vincent - V. Danzi*

16.10 Sepsis and AKI: why many trials fail?	<i>J.L. Vincent</i>
16.30 AKI in Sepsis: mechanisms, phenotype and biotype	<i>R. Bellomo</i>
16.50 Different phenotypes in Sepsis	<i>J. Kellum</i>
17.10 Postoperative AKI and Sepsis management	<i>A. Shaw</i>
17.30 Pharmacological management of septic AKI	<i>L. Forni</i>
17.50 Sequential extracorporeal therapy in Sepsis	<i>C. Ronco</i>
18.10 Discussion	
18.20 ADJOURN	

ROOM TIZIANO - CRRT PATH

SESSION 1 - EVOLUTION OF CRRT TECHNOLOGY

Chairmen: *M. Ostermann - TBA*

16.10 Membranes for CRRT	<i>W. Clark</i>
16.30 Apheresis in acute patients	<i>A. Ramunni</i>
16.50 Anticoagulation strategies	<i>G. Villa</i>
17.10 The importance of Vascular Access	<i>Z. Ricci</i>
17.30 Moving towards MOST-ECOS	<i>T. Rimmelé</i>
17.50 Data collection and management	<i>M. Bell</i>
18.10 Discussion	
18.20 ADJOURN	

Room Palladio

18.40 Opening Ceremony	
18.55 International Vicenza Award	
19.00 Course Partner Recognition	
19.15 The contribute of ADQI in the last 20 years	<i>J. Kellum</i>
19.30 Welcome Reception	

ROOM GIOTTO - AKI PATH

SESSION 2 - AKI DEFINITION & STAGING

Chairmen: *J. Kellum - C. Ronco*

08.00 The continuum of AKI	<i>R. Mehta</i>
08.20 Acute Kidney Stress: what is it?	<i>J. Kellum</i>
08.40 From AKI to AKD	<i>K. Kashani</i>
09.00 Kidney disease progression: role of Sirt-3	<i>A. Benigni</i>
09.20 Patterns of AKI Recovery	<i>L. Forni</i>
09.40 BREAK	

SESSION 3 - KIDNEY DAMAGE AND FUNCTION BIOMARKERS

Chairmen: *L. Forni - M. Plebani*

10.00 Is Creatinine still useful in AKI?	<i>R. Bellomo</i>
10.20 Incorporating Biomarkers in AKI definition	<i>C. Ronco</i>
10.40 Biomarkers of AKI risk before the insult	<i>A. Zarbock</i>
11.00 Results from the RUBY Trial (CCL14)	<i>J. Kellum</i>
11.20 Discussion	

11.30 Industry-Sponsored Symposium 1

13.00 LUNCH

13.30 Industry-Sponsored Symposium 2

SESSION 4 - UVA - IRRIV Session - AKI MECHANISMS AND CI-AKI

Chairmen: *M. Okusa - R. Bellomo*

15.00 Kidney bioenergetics in AKI	<i>M. Okusa</i>
15.20 Regulatory T-cells for prognosis and therapy of AKI	<i>R. Sharma</i>
15.40 Computable AKI Phenotypes for EHR Studies	<i>J. Scialla</i>
16.00 Contrast-induced AKI today	<i>TBA</i>
16.20 CI-AKI in Interventional cardiology	<i>F. Ronco</i>
16.30 BREAK	

SESSION 5 - AKI PATHWAYS

Chairmen: *A. Shaw - P. Navalesi*

17.00 Renal Angina Index, NGAL, FST	<i>S. Goldstein</i>
17.20 Using KDIGO Bundles to prevent AKI	<i>A. Zarbock</i>
17.40 AKI and fluid management	<i>R. Bellomo</i>
18.00 AKI and antibiotics	<i>J. Kellum</i>
18.20 Discussion	
18.30 ADJOURN	

ROOM TIZIANO - CRRT PATH

SESSION 2 - INITIATION and DISCONTINUATION

Chairmen: *S. Bagshaw - S. Romagnoli*

08.00 Today's indication to CRRT	<i>S. Romagnoli</i>
08.20 Can we use biomarkers to start CRRT?	<i>A. Zarbock</i>
08.40 Parameters to suggest discontinuation	<i>G. A. Romero Gonzalez</i>
09.00 SPECIAL LECTURE: CRRT initiation: the STARRT Trial	<i>S. Bagshaw</i>
09.40 BREAK	

SESSION 3 - CRRT PRACTICE

Chairmen: *TBA*

10.00 Net UF during CRRT and mortality	<i>R. Murugan</i>
10.20 Net UF during CRRT and heterogeneity of effect	<i>R. Bellomo</i>
10.40 The impact of fast fluid removal on the heart	<i>L. Forni</i>
11.00 Choice and impact of RRT modality	<i>G. Villa</i>
11.20 NET UF and renal recovery	<i>R. Murugan</i>

11.30 Industry-Sponsored Symposium 1

13.30 Industry-Sponsored Symposium 2

SESSION 4 - QUALITY ASSURANCE IN CRRT

Chairmen: *R. L. Mehta - C. Ronco*

15.00 A general approach to Quality policy in CRRT	<i>C. Ronco</i>
15.20 Quality measures in CRRT (ADQI definitions)	<i>R. L. Mehta</i>
15.40 Measuring the quality of a CRRT programme	<i>S. Bagshaw</i>
16.00 Using Artificial intelligence to control quality	<i>K. Kashani</i>
16.20 Ensuring adequate delivery of CRRT dose	<i>G. Villa</i>
16.30 Ensuring nursing competence and training	<i>I. Baldwin</i>

SESSION 5 - CRRT PRACTICAL AND FUTURE OPTIONS

Chairmen: *I. Baldwin - Z. Ricci*

17.00 Hourly fluid balance in patients receiving CRRT	<i>I. Baldwin</i>
17.20 The promise of MCO membranes for CRRT	<i>T. Reis</i>
17.40 Removal of antibiotics in CRRT	<i>F. Ferrari</i>
18.00 Nutrition during CRRT in ICU patients	<i>J. Cerda</i>
18.20 Preventing complications during CRRT	<i>A. Shaw</i>
18.30 Integrating ECMO and CRRT	<i>Z. Ricci</i>

ROOM CANOVA - MTE PATH

10.00 How do I manage Sepsis

J.L. Vincent

10.50 How do I manage AKI

R.L. Mehta

11.30 Industry-Sponsored Symposium 1

13.30 Industry-Sponsored Symposium 2

15.00 How do I monitor CRRT

I. Baldwin

15.50 How to manage vascular access

M. Joannidis

SESSION 6 - HEART, LUNG AND THE KIDNEY

Chairmen: *F. Husain-Syed - M. Joannidis*

08.00 Lung and Kidney-Native and artificial organ interactions	<i>F. Husain-Syed</i>
08.20 Mechanisms of lung injury associated AKI	<i>M. Joannidis</i>
08.40 Mechanical Ventilation and Kidney Function	<i>L. Forni</i>
09.00 New insights into cardio-renal interaction: role of NGAL	<i>Y. Shacham</i>
09.20 Lung and Kidney: the best fluid management	<i>P. Murray</i>
09.40 BREAK	

SESSION 7 - PERIOPERATIVE KIDNEY CARE

(reports from the ADQI/POQI consensus)

Chairmen: *J. Prowle - A. Shaw*

10.00 Epidemiology and Pathophysiology of perioperative AKI	<i>L. Forni</i>
10.20 AKI a sentinel perioperative complication	<i>J. Prowle</i>
10.40 Definitions of perioperative AKI: The Cambridge resolutions	<i>A. Shaw</i>
11.00 Prevention Strategies for perioperative AKI	<i>S. Bagshaw</i>
11.20 Outcomes after peri-operative AKI	<i>M. Ostermann</i>

11.30 Industry-Sponsored Symposium 3

13.00 LUNCH

13.30 Industry-Sponsored Symposium 4

SESSION 8 - Mayo Clinic - IRRIV Session - AKI INSIGHTS

Chairmen: *TBA*

15.00 Augmented human intelligence and AKI management	<i>K. Kashani</i>
15.20 AKI among women: gender influence	<i>A. Kattah</i>
15.40 Management of patients with organ transplant in ICU	<i>H. Amer</i>
16.00 Diuretic resistance in volume overloaded patients	<i>K. Kashani</i>
16.20 Role of microRNA and extracellular vesicles in AKI and sepsis	<i>V. Cantaluppi</i>
16.40 The meaning of the IRRIV test	<i>S. Samoni</i>
17.00 BREAK	

SESSION 9 - AKI MONITORING AND PREVENTION

Chairmen: *TBA*

17.20 The Urea/Creatinine Ratio	<i>J. Prowle</i>
17.50 Remote ischemic preconditioning	<i>TBA</i>
18.10 Mechanical Circulatory Support and AKI	<i>A. Kazory</i>
18.20 Discussion	
18.30 ADJOURN	

SESSION 6 - CRRT in 2020

Chairmen: *J. Cerda - P. Honoré*

08.00 CRRT in 2020: reflections of 50 years of CCM	<i>R. Bellomo</i>
08.20 Extracorporeal lung support	<i>TBA</i>
08.40 Extracorporeal support in Heart Failure	<i>TBA</i>
09.00 Extracorporeal support in Liver Failure	<i>J. Wendon</i>
09.20 Extracorporeal support in Infants	<i>S. Goldstein</i>
09.40 BREAK	

SESSION 7 - EXTRACORPOREAL TREATMENTS IN SEPSIS

Chairmen: *S. De Rosa - A. Zarbock*

10.00 Rationale and current options	<i>C. Ronco</i>
10.20 Impact of volume exchange	<i>P. Honoré</i>
10.40 Impact of membrane permeability	<i>G. Villa</i>
11.00 Endotoxin removal in 2020	<i>S. De Rosa</i>
11.20 Cytokine adsorption	<i>V. Cantaluppi</i>

11.30 Industry-Sponsored Symposium 3

13.30 Industry-Sponsored Symposium 4

SESSION 8 - CRRT and NEW TECHNOLOGY

Chairmen: *S. Romagnoli - TBA*

15.00 The promise of adsorption	<i>C. Ronco</i>
15.20 Automated biofeedback to ensure treatment delivery	<i>S. Romagnoli</i>
15.40 Temperature control in CRRT	<i>M. Broman</i>
16.00 Real Time GFR measurement	<i>S. Goldstein</i>
16.20 New Membranes for CRRT	<i>G. Castellano</i>
16.40 Should we use PD in the ICU?	<i>TBA</i>
17.00 BREAK	

SESSION 9 - SPECIAL ISSUES IN CRITICAL CARE NEPHROLOGY

Chairmen: *C. Ronco - TBA*

17.20 Chloride and Cardiorenal Syndrome	<i>A. Kazory</i>
17.50 Transitioning to chronic RRT	<i>J. Cerda</i>
18.10 ACE inhibitors in ICU: should we use them?	<i>TBA</i>
18.20 Discussion	
18.30 ADJOURN	

11.30 Industry-Sponsored Symposium 3

13.30 Industry-Sponsored Symposium 4

15.00 How do I use Biomarkers

L. Forni and S. Goldstein

15.50 How can I prevent AKI?

A. Zarbock